Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn

Obesity, Diabetes Blockbusters Lead 36% Revenue Growth

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lilly now expects to bring in between $45.4bn and $46.6bn in total revenue this year, thanks mainly to continued growth for Mounjaro and Zepbound.

Lilly corporate center
Lilly posted 36% year-over-year growth during Q2 2024 • Source: Shutterstock

Eli Lilly and Company said supply issues for its GLP-1/GIP dual agonist tirzepatide – the active ingredient in type 2 diabetes drug Mounjaro and obesity treatment Zepbound – largely have been resolved. The company increased its full-year overall sales guidance for 2024 by $3bn when it reported second quarter earnings on 8 August, largely on the strength of those two products, but with some contribution from its breast cancer drug Verzenio (abemaciclib).

Key Takeaways

  • Already on a growth trajectory, Lilly reported 36% year-over-year revenue growth during Q2 thanks to exponential sales increases for Mounjaro and a strong launch for Zepbound.

CEO David Ricks pointed to the May announcement that Lilly was committing an additional $5.3bn to building out its Lebanon,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Nancy Tests SPARC-1036

Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.